Human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes (HIV-1 CTL epitopes)

Human immunodeficiency virus type 1 (HIV-1) cytotoxic T-lymphocyte (CTL) epitopes are short peptide sequences, typically 8-11 amino acids long, derived from viral proteins like Gag, Pol, and Nef (Goulder & Watkins, 2008). These epitopes are presented on the surface of infected cells by Major Histocompatibility Complex (MHC) class I molecules, where they are recognized by the T-cell receptors (TCR) of CD8+ T-cells (NIH/LANL HIV Database). This recognition triggers the release of cytotoxic molecules such as perforin and granzymes, leading to the apoptosis of the infected cell and the suppression of viral replication (Hanke, 2019). CTL epitopes are central to the development of T-cell-based HIV vaccines, which aim to elicit broad and potent cellular immune responses to control or prevent infection (Mothe et al., 2015). However, the high genetic diversity and rapid mutation rate of HIV-1 frequently lead to immune escape, where mutations within these epitopes prevent MHC binding or TCR recognition (Goulder & Watkins, 2004). Furthermore, the effectiveness of targeting specific epitopes is constrained by the host's HLA (Human Leukocyte Antigen) profile, necessitating the inclusion of multiple conserved epitopes in vaccine designs to ensure broad population coverage (Korber et al., 2017).

Other names

HIV-1 CD8+ T-cell epitopesHIV-1 MHC class I-restricted epitopesHIV-1 T-cell epitopesHIV-1 CTL targets

Induction of antigen-specific CD8+ T-lymphocyte responses to recognize and eliminate HIV-1 infected cells through the recognition of viral peptide-MHC class I complexes.